Vergoeding 2018-2022 voor ATC-subgroep A10BJ : Glucagonachtig peptide-1-agonisten (glp-1-agonisten)
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| A10BJ01 Exenatide (Bydureon ®) | 879.410 | 730.960 | 588.480 | 478.400 | 357.420 |
| A10BJ02 Liraglutide (Victoza ®) | 13.666.600 | 13.785.300 | 11.632.600 | 9.275.700 | 17.689.100 |
| A10BJ03 Lixisenatide (Lyxumia ®) | 90.202 | 83.417 | 65.761 | 42.772 | 35.806 |
| A10BJ05 Dulaglutide (Trulicity ®) | 2.757.000 | 2.640.200 | 3.586.600 | 4.413.300 | 7.303.000 |
| A10BJ06 Semaglutide (Ozempic ®) | 380.020 | 9.289.800 | 24.153.100 | 36.169.000 | 54.934.500 |
| Totaal | 17.773.232 | 26.529.677 | 40.026.541 | 50.379.172 | 80.319.826 |